<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401971</url>
  </required_header>
  <id_info>
    <org_study_id>DREAM-002</org_study_id>
    <nct_id>NCT02401971</nct_id>
  </id_info>
  <brief_title>Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer</brief_title>
  <acronym>ITAGC</acronym>
  <official_title>Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer : A Multicenter, Randomized, Controlled and Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wang Jufeng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Henan University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhengzhou University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent clinical studies have demonstrated a reduction of irinotecan (CPT-11) gastrointestinal
      toxicities when the CPT-11 is administered in combination with thalidomide in patients with
      diagnosis of gastric cancer. The main purpose of this study is to investigate the efficacy
      and safety of thalidomide and CPT-11 in advanced gastric cancer. The investigators will also
      manage to find out the possible interactions between CPT-11 pharmacokinetics and thalidomide
      to explain the previously described gastrointestinal toxicity reduction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, multi-center, controlled clinical trial, aimed to evaluate
      efficacy and tolerability of thalidomide and CPT-11 in advanced gastric cancer. A total of
      900 patients are planned to be enrolled into the study. Patients with diagnosis of advanced
      gastric cancer will be randomized into two groups, and be treated with thalidomide+ CPT-11 or
      CPT-11, respectively. The primary end point is time to progression (TTP), and the secondary
      end points include efficacy, overall survival (OS) and the occurrence of delayed diarrhea.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to progression(TTP)</measure>
    <time_frame>up to 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete response rate (CRR) for advanced gastric cancer</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (thalidomide+CPT-11)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive CPT-11 180 mg/m^2 ivgtt ,over 90 minutes on day 1, every 21 days for one cycle, four cycles ,and oral thalidomide 100 mg/d qn. Maintenance therapy with thalidomide in the same dose is performed until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (CPT-11)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive CPT-11 180 mg/m^2 ivgtt ,over 90 minutes on day 1, every 21 days for one cycle, four cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm A (thalidomide+CPT-11)</arm_group_label>
    <other_name>Kevadon</other_name>
    <other_name>Synovir</other_name>
    <other_name>THAL</other_name>
    <other_name>Thalomid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPT-11</intervention_name>
    <description>Given Ivgtt</description>
    <arm_group_label>Arm A (thalidomide+CPT-11)</arm_group_label>
    <arm_group_label>Arm B (CPT-11)</arm_group_label>
    <other_name>Irinotecan hydrochloride</other_name>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>irinotecan</other_name>
    <other_name>U-101440E</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18y &lt;Age&lt;75y

          -  Patients with histologically proven tumor focus will be eligible for this protocol

          -  Measurable or assessable disease

          -  At least 4 weeks since last chemotherapy ;chemotherapy regimens without Irinotecan

          -  No hepatic, renal and hematopoietic dysfunction; no hemorrhage of digestive
             tract,obstructive jaundice, gastrointestinal perforation or obstruction

          -  ECOG PS:0-2

          -  Expected OS â‰¥ 3 months

        Exclusion Criteria:

          -  obstruction of digestive tract, thrombosis or other intolerant side effects during
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang Jufeng</last_name>
    <role>Study Chair</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qin Yanru</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhou Yun</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Provincial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhang Zhongmian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guo Yanzhen</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang Jufeng</last_name>
    <phone>13783583966</phone>
    <email>13783583966@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Jufeng</last_name>
      <phone>13783583966@163.com</phone>
      <email>13783583966@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>March 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2015</study_first_posted>
  <last_update_submitted>March 27, 2015</last_update_submitted>
  <last_update_submitted_qc>March 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Wang Jufeng</investigator_full_name>
    <investigator_title>Master</investigator_title>
  </responsible_party>
  <keyword>Thalidomide</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Second Line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

